Interferon-beta

• 

  Subject Areas on Research

  • A Novel Mycovirus Evokes Transcriptional Rewiring in the Fungus Malassezia and Stimulates Beta Interferon Production in Macrophages. 
  • A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. 
  • A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. 
  • A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. 
  • ADAP2 Is an Interferon Stimulated Gene That Restricts RNA Virus Entry. 
  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 
  • An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. 
  • Bone protection by inhibition of microRNA-182. 
  • Cloned endothelium derived from autoimmune vascular disease retain structural and functional characteristics of normal endothelial cells. 
  • Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. 
  • Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. 
  • Cytokine expression by models of human trophoblast as assessed by a semiquantitative reverse transcription-polymerase chain reaction technique. 
  • Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. 
  • Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts. 
  • Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. 
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. 
  • Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? 
  • Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials. 
  • GW112, a novel antiapoptotic protein that promotes tumor growth. 
  • Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity. 
  • IFN-beta inhibits human Th17 cell differentiation. 
  • IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. 
  • IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. 
  • Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling. 
  • Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. 
  • Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. 
  • Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. 
  • Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon lambda protects the female reproductive tract against Zika virus infection. 
  • Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. 
  • Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. 
  • Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. 
  • NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses. 
  • Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity. 
  • Oncolytic virus-derived type I interferon restricts CAR T cell therapy. 
  • Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. 
  • Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. 
  • Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. 
  • Regulation of microglial function by interferons. 
  • Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. 
  • STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. 
  • The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia. 
  • The induction of HMGB1 release from RAW 264.7 cells by transfected DNA. 
  • The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. 
  • The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. 
  • The small GTPase RAB1B promotes antiviral innate immunity by interacting with TNF receptor-associated factor 3 (TRAF3). 
  • Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. 
  • Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). 
  • Type I interferon pathway in adult and juvenile dermatomyositis. 
  • Update: biomarkers for idiopathic inflammatory myopathies. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • [NLRP3 inflammasome and multiple sclerosis/EAE]. 
• 

  Keywords of People

  • Shinohara, Mari L., Associate Professor of Immunology, Immunology